CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Alcon acquires micro-stent company Transcend Medical

Eye care company Alcon has acquired Transcend Medical, a US-based company that produces a micro-stent device useful in the treatment of glaucoma

Alcon acquires microstent company Transcend Medical

Alcon has announced that it has acquired Transcend Medical, a US-based company that produces minimally-invasive surgical devices to treat glaucoma.

Transcend Medical recently developed a micro-stent which is surgically implanted just below the surface of the eye for the treatment of less-severe glaucoma.

The device is designed to reduce intraocular pressure (IOP) by enhancing the natural drainage pathways of the eye with minimal disruption to surrounding tissue.

In a randomised study of over 500 people with mild-to-moderate glaucoma undergoing cataract surgery, patients who received the micro-stent experienced a 20% reduction in IOP compared to those who did not.

Alcon chief executive, Mike Ball, said he hoped the company’s acquisition of Transcend Medical would improve non-invasive treatment of glaucoma.

Mr Ball commented: “We expect the MIGS (minimally invasive glaucoma surgery) technology to be a great addition to our device pipeline and to establish Alcon’s presence in this new surgical category to treat glaucoma.

He added: “If approved, it will provide a less invasive means of lowering IOP than traditional invasive glaucoma surgery, with the goal of lowering the dependency of topical ocular medication.”

Alcon is a division of the multinational pharmaceutical company Novartis.

Image credit: Transcend Medical